Abstract
Radiochemotherapy represents the cornerstone of the treatment for patients affected by locally advanced non small cell lung cancer. Nevertheless, to date there is no agreement concerning how the standard therapy is and many questions are still open. Two timing modalities have been proposed to combine chemotherapy and radiotherapy: after many phase II/III have tested concurrent or sequential approach, concurrent radiochemotherapy is today considered as the treatment of choice, despite the role of induction or consolidation chemotherapy is still unclear. Cisplatin alone or in combination is considered as the reference drug in combination with chemotherapy, but in the last decades, many trials have demonstrated that new-generation drugs, which are routinely used in metastatic disease, may be used during radiotherapy and may enhance its tumor control rate, frequently having a radiosentizing power. Finally, in the era of molecular biomarkers and target therapies, new approaches could dramatically change the physicians view about the drug choice giving the opportunity of a tailored therapy customized on the single patient also in the treatment of locally advanced non-small cell lung cancer.
Keywords: Non-small cell lung cancer, chemotherapy, radiotherapy, target therapy, radiosensitizing agents
Current Drug Therapy
Title: Radiochemotherapy for Non Small Cell Lung Cancer
Volume: 5 Issue: 3
Author(s): Orazio Caffo and Viviana Murgia
Affiliation:
Keywords: Non-small cell lung cancer, chemotherapy, radiotherapy, target therapy, radiosensitizing agents
Abstract: Radiochemotherapy represents the cornerstone of the treatment for patients affected by locally advanced non small cell lung cancer. Nevertheless, to date there is no agreement concerning how the standard therapy is and many questions are still open. Two timing modalities have been proposed to combine chemotherapy and radiotherapy: after many phase II/III have tested concurrent or sequential approach, concurrent radiochemotherapy is today considered as the treatment of choice, despite the role of induction or consolidation chemotherapy is still unclear. Cisplatin alone or in combination is considered as the reference drug in combination with chemotherapy, but in the last decades, many trials have demonstrated that new-generation drugs, which are routinely used in metastatic disease, may be used during radiotherapy and may enhance its tumor control rate, frequently having a radiosentizing power. Finally, in the era of molecular biomarkers and target therapies, new approaches could dramatically change the physicians view about the drug choice giving the opportunity of a tailored therapy customized on the single patient also in the treatment of locally advanced non-small cell lung cancer.
Export Options
About this article
Cite this article as:
Caffo Orazio and Murgia Viviana, Radiochemotherapy for Non Small Cell Lung Cancer, Current Drug Therapy 2010; 5 (3) . https://dx.doi.org/10.2174/157488510791561084
DOI https://dx.doi.org/10.2174/157488510791561084 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cytochrome P450 Drug Metabolizing Enzymes in Roma Population Samples: Systematic Review of the Literature
Current Medicinal Chemistry Flavonoids, Breast Cancer Chemopreventive and/or Chemotherapeutic Agents
Current Medicinal Chemistry Synthesis and Preliminary Evaluation of n.c.a. Iodoquine: A Novel Radiotracer with High Uptake in Cells with High ALDH1 Expression
Current Radiopharmaceuticals Targeting the mTOR Pathway in Tumor Malignancy
Current Cancer Drug Targets Functionalized Biogenic Nanoparticles for Use in Emerging Biomedical Applications: A Review
Current Nanomaterials D-Galactose as a Vector for Prodrug Design
Current Topics in Medicinal Chemistry Dietary Phenolic Acids and Flavonoids as Potential Anti-Cancer Agents: Current State of the Art and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry PET Molecular Imaging of Hypoxia in Ischemic Stroke: An Update
Current Vascular Pharmacology Review: Technegas - 99mTc-Metal Core Graphite Nanoparticles for Pulmonary Ventilation Imaging
Current Radiopharmaceuticals A Sialic Acid-Specific Lectin from the Mushroom Paecilomyces Japonica that Exhibits Hemagglutination Activity and Cytotoxicity
Protein & Peptide Letters Sirtuin Modulators: Mechanisms and Potential Clinical Implications
Current Medicinal Chemistry Medical Applications of Implantable Drug Delivery Microdevices Based on MEMS (Micro-Electro-Mechanical-Systems)
Current Pharmaceutical Biotechnology Erdafitinib as a Novel and Advanced Treatment Strategy of Metastatic Urothelial Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Cinnamic Acid Derivatives as Anticancer Agents-A Review
Current Medicinal Chemistry The Functions of F-box Proteins in Regulating the Epithelial to Mesenchymal Transition
Current Pharmaceutical Design Speciation of Metal Complexes of Medicinal Interest: Relationship between Solution Equilibria and Pharmaceutical Properties
Current Medicinal Chemistry Nuclear Receptor SHP as a Potential Therapeutic Target for Liver Cancer
Current Cancer Therapy Reviews Evaluation of Direct Effect of Testosterone on NGEP and LM O1 Expression in LNCaP Prostate Cancer Cells
Current Biomarkers (Discontinued) Cytokine/Antibody Complexes: An Emerging Class of Immunostimulants
Current Pharmaceutical Design Cardiovascular Biology of Interleukin-6
Current Pharmaceutical Design